| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunoprecipitation; human; fig 3
- immunocytochemistry; human; 1:1000
- western blot; human; 1:1000; fig 1
| Li J, Zhang S, Hu Q, Zhang K, Jin J, Zheng X, et al. The NKD1/Rac1 feedback loop regulates the invasion and migration ability of hepatocarcinoma cells. Sci Rep. 2016;6:26971 pubmed publisher |
| Rodgers S, Ferguson D, Mitchell C, Ooms L. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases. Biosci Rep. 2017;37: pubmed publisher |
| Amoroso M, Matassa D, Agliarulo I, Avolio R, Lu H, Sisinni L, et al. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. Cell Death Dis. 2016;7:e2522 pubmed publisher |
| Yu R, Yu B, Chen J, Lv X, Yan Z, Cheng Y, et al. Anti-tumor effects of Atractylenolide I on bladder cancer cells. J Exp Clin Cancer Res. 2016;35:40 pubmed publisher |
| Kong D, Li S, Du Z, Liu C, Liu B, Li C, et al. BAG3 elevation inhibits cell proliferation via direct interaction with G6PD in hepatocellular carcinomas. Oncotarget. 2016;7:700-11 pubmed publisher |
| Qin H, Sha J, Jiang C, Gao X, Qu L, Yan H, et al. miR-122 inhibits metastasis and epithelial-mesenchymal transition of non-small-cell lung cancer cells. Onco Targets Ther. 2015;8:3175-84 pubmed publisher |
| Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, et al. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway. Oncotarget. 2015;6:25281-94 pubmed publisher |
| Cohen Solal K, Boregowda R, Lasfar A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14:137 pubmed publisher |
| Cao P, Feng F, Dong G, Yu C, Feng S, Song E, et al. Estrogen receptor α enhances the transcriptional activity of ETS-1 and promotes the proliferation, migration and invasion of neuroblastoma cell in a ligand dependent manner. BMC Cancer. 2015;15:491 pubmed publisher |
| Johnson S, Dong X, Vijg J, Suh Y. Genetic evidence for common pathways in human age-related diseases. Aging Cell. 2015;14:809-17 pubmed publisher |
| Li J, Li Q, Du H, Wang Y, You S, Wang F, et al. Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter. Int J Mol Sci. 2015;16:12560-77 pubmed publisher |
| Khabele D, Kabir S, Dong Y, Lee E, Rice V, Son D. Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF. J Cancer. 2014;5:670-8 pubmed publisher |
| Chanvorachote P, Chunhacha P, Pongrakhananon V. Caveolin-1 induces lamellipodia formation via an Akt-dependent pathway. Cancer Cell Int. 2014;14:52 pubmed publisher |
| Park M, Kim B, Dong S, Lee S, Kim D, Rho S. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1? expression. Oncotarget. 2014;5:4935-44 pubmed |
| Ren W, Liu Y, Wan S, Fei C, Wang W, Chen Y, et al. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS ONE. 2014;9:e96816 pubmed publisher |
| Muniz Feliciano L, Van Grol J, Portillo J, Liew L, Liu B, Carlin C, et al. Toxoplasma gondii-induced activation of EGFR prevents autophagy protein-mediated killing of the parasite. PLoS Pathog. 2013;9:e1003809 pubmed publisher |
| Song T, Wang L, Mo Z, Mao L, Ma X, Niu R, et al. Expression of p-Akt in ovarian serous carcinoma and its association with proliferation and apoptosis. Oncol Lett. 2014;7:59-64 pubmed |
| Juvin V, Malek M, Anderson K, Dion C, Chessa T, Lecureuil C, et al. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. PLoS ONE. 2013;8:e75045 pubmed publisher |
| Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, et al. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther. 2013;6:1373-84 pubmed publisher |
| Dobbin Z, Landen C. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14:8213-27 pubmed publisher |
| De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F, et al. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS ONE. 2013;8:e55362 pubmed publisher |
| Lee H, Kim J, Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PLoS ONE. 2012;7:e50624 pubmed publisher |
| McCubrey J, Steelman L, Chappell W, Abrams S, Montalto G, Cervello M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3:954-87 pubmed |
| He J, Xu Q, Wang M, Li C, Qian X, Shi Z, et al. Oral administration of apigenin inhibits metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian tumor model. Int J Mol Sci. 2012;13:7271-82 pubmed publisher |
| Virtakoivu R, Pellinen T, Rantala J, Perälä M, Ivaska J. Distinct roles of AKT isoforms in regulating ?1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell. 2012;23:3357-69 pubmed publisher |
| Saji M, Narahara K, McCarty S, Vasko V, La Perle K, Porter K, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene. 2011;30:4307-15 pubmed publisher |
| Kumar R, Blakemore S, Ellis C, Petricoin E, Pratt D, Macoritto M, et al. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. BMC Genomics. 2010;11:419 pubmed publisher |
| Smith D, Patel S, Raffoul F, Haller E, Mills G, Nanjundan M. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ. 2010;17:1867-81 pubmed publisher |
| Gujral T, MacBeath G. A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation. PLoS ONE. 2010;5:e10024 pubmed publisher |
